510(k) Report

510(k) · Cleared

Cleared

VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mL

K151817510(k) TraditionalCleared Feb 18, 2016227-day reviewClass II21 CFR 866.1640

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

bioMerieux, Inc. · NGZ Susceptibility Test Plate, Antifungal

Cleared on Feb 18, 2016 as substantially equivalent to K133952 (bioMerieux, Inc., 2014) after a 227-day review. Its family tree reaches back 2 generations to 2010. 2 later devices descend from it.

Decided
Feb 18, 2016
Review
227 days
Class
Class II
Product code
NGZ
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K092454 (2010). 2 later devices descend from it, 1 citing it directly.

Descendants, by year cleared 2022: 1 descendant cleared2024: 1 descendant clearedK092454 · Vitek 2 Yeast Voriconazole · bioMerieux, Inc. · 2010K133952 · Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast Flucytosine · bioMerieux, Inc. · 20142010201520202025
Descendants, by generation 1 generation forward: 1 descendant2 generations forward: 1 descendant K133952 · Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast Flucytosine · bioMerieux, Inc. · 2014K092454 · Vitek 2 Yeast Voriconazole · bioMerieux, Inc. · 20100
  1. Root · 2 generations backK092454 Vitek 2 Yeast VoriconazolebioMerieux, Inc. · 2010
  2. 1 generation backK133952 Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast FlucytosinebioMerieux, Inc. · 2014
  3. This deviceK151817 VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mLbioMerieux, Inc. · 2016
  4. Descendant · cites it directly · 1 of its ownK213899 VITEK 2 AST-Yeast Caspofungin (<=0.125 - >=8 µg/mL), VITEK 2 AST-YS…bioMerieux, Inc. · 2022
  5. Descendant · 2 generations on · 0 of its ownK232963 VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc. · 2024

Most influential descendants

Showing 2 of 2 · See all
  • K213899VITEK 2 AST-Yeast Caspofungin (<=0.125 - >=8 µg/mL), VITEK 2 AST-YS Caspofungin (<=0.125…bioMerieux, Inc. · 2022 · cites it directly1descendant
  • K232963VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc. · 2024 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K092454Vitek 2 Yeast VoriconazolebioMerieux, Inc.2010—
−1K133952Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast FlucytosinebioMerieux, Inc.2014—
0 (this device)K151817VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mLbioMerieux, Inc.2016—
+1K213899VITEK 2 AST-Yeast Caspofungin (<=0.125 - >=8 µg/mL), VITEK 2 AST-YS…bioMerieux, Inc.2022—
+2K232963VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc.2024—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202210
202410
FIG. 1 — Lineage of K151817, 2010–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NGZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NGZ device

  1. #1 K232963 VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >=…score 8.4 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K133952Vitek 2 Ast YS Flucytosine, Vitek 2 Ast Yeast Flucytosine
Summary page 4
…timicrobial susceptibility test powder Product Code NGZ Common Name: VITEK® 2 AST-YS Caspofungin C. Predicate Device: VITEK® 2 AST-YS Flucytosine (K133952) D. 510(k) Summary: VITEK® 2 AST-YS Caspofungin is designed for antifungal susceptibility testing of Candida species and is inte…
bioMerieux, Inc.2014—

Also cleared against K133952: 1 other device →

What descends from it? (2)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K213899VITEK 2 AST-Yeast Caspofungin (<=0.125 - >=8 µg/mL), VITEK 2 AST-YS Caspofungin (<=0.125…bioMerieux, Inc.20221

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 6 years and passes through 1 company; a new generation was cleared every 4.2 years on median.
  • None of the 2 ancestors has a recall.
  • Of its descendants, K213899 (bioMerieux, Inc., 2022) has gone furthest, with 1 descendant of its own.
  • 1 other device also cites its predicate K133952.

How does its category compare?

All NGZ devices

NGZ Susceptibility Test Plate, Antifungal: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.

FDA decisions per year · NGZ

1in 2025

2009: 32010: 22014: 32016: 22018: 12021: 12023: 32024: 22025: 1
2007high 3 (2009) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NGZ

204in 2023

2009: 326 days median2014: 232 days median2023: 204 days median
2007high 326 (2009) · low 204 (2023)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NGZ

2in 2022

2022: 2
2007high 2 (2022) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NGZ

1in 2024

2011: 12014: 12015: 12016: 92017: 162018: 102021: 82022: 32023: 32024: 1
2007high 16 (2017) · low 0 (2007)2025

MAUDE reports naming product code NGZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
2009332600
20102—00
20110—01
20120—00
20130—00
2014323201
20150—01
20162—09
20170—016
20181—010
20190—00
20200—00
20211—08
20220—23
2023320403
20242—01
20251—00
20260—0—

What is it indicated for?

VITEK® 2 AST-YS Caspofungin is designed for antifungal susceptibility testing of Candida species and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 Yeast Caspofungin is a quantitative test. Caspofungin has been shown to be active against most isolates of the microorganisms listed below, according to the FDA label for this antifungal.…

Read the full statement (138 words)

VITEK® 2 AST-YS Caspofungin is designed for antifungal susceptibility testing of Candida species and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 Yeast Caspofungin is a quantitative test. Caspofungin has been shown to be active against most isolates of the microorganisms listed below, according to the FDA label for this antifungal.

Active in vitro and clinical infections:

Candida albicans

Candida glabrata

Candida guilliermondii

Candida krusei

Candida parapsilosis

Candida tropicalis

The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., S. pneumoniae, and clinically significant yeast.

Indications for use as stated in the FDA summary.

Also cleared against K133952

1 other device cites the same predicate.

  • K151923VITEK 2 AST-Yeast Micafungin (0.06-8 mcg/mL)bioMerieux, Inc. · 2016

More from bioMerieux, Inc.

281 FDA decisions under this applicant name. See the company

  • K260283VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)bioMerieux, Inc. · 2026
  • K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystembioMerieux, Inc. · 2026
  • K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc. · 2026
  • K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc. · 2025
  • K234012Vitek Compact ProbioMerieux, Inc. · 2025

Recent decisions in NGZ

The NGZ category page

  • K243738The Sensititre YeastOne Susceptibility System with Micafungin in the dilution range of 0.008-16 µg/mLThermo Fisher Scientific · 2025
  • K232967VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)bioMerieux, Inc. · 2024
  • K232963VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)bioMerieux, Inc. · 2024
  • K231433The Sensititre YeastOne Susceptibility System with Rezafungin in the dilution range of 0.008-8ug/mLThermo Fisher Scientific · 2023
  • K221198Sensititre YeastOne Susceptibility System with Fluconazole in the dilution range of 0.12-128ug/mLThermo Fisher Scientific · 2023

https://510kreport.com/device/K151817 · printed Nov 6, 2026

Cite this page

510(k) Report. “K151817: VITEK 2 AST-YS Caspofungin <=0.125 - >=8 ug/mL.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K151817

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026